L35
The objective of this multi-center, pivotal registration study was to establish the efficacy and safety of a specific T cell immunoregulatory synthetic peptide therapy (Cat-PAD). A promising therapeutic profile had been demonstrated in the preceding clinical investigative program. METHODS: Male and female, adult and adolescent patients were eligible: with a minimum 2-year history of moderate rhinoconjunctivitis; defined symptomatic, skin prick and IgE parameters; to have a cat resident at home. An FEV 1 <80% of predicted, or confounding allergies, were exclusions. Subjects (1,408 recruited) were randomised, double-blind and equally, to intradermally administered placebo, Cat-PAD 6nmol/4weeks x4 or Cat-PAD 6nmol/4weeks x8. Safety was assessed by adverse event reporting and clinical monitoring. The primary efficacy outcome was mean daily Combined Score (CS), collected through weeks 52-54 after the start of therapy. CS was a composite of Rescue Medication Score (RMS) and Total Rhinoconjunctivitis Symptom Score (TRSS); weighted 8:1 respectively. Statistical analysis of active groups compared to placebo was by ANCOVA, with baseline as a covariate. RESULTS: CS results, versus placebo (414 subjects No tolerability or safety issues were observed. CONCLUSIONS: No differences between active treatments and placebo were observed in this field study. This may have arisen from the study population being pre-tolerized by the mandated cat exposure.
